New Jersey Headlines

Angelman Syndrome Market, Size, Share, Trends, Epidemiology Forecast till 2030

 Breaking News
  • No posts were found

Angelman Syndrome Market, Size, Share, Trends, Epidemiology Forecast till 2030

August 10
17:11 2020
Angelman Syndrome Market, Size, Share, Trends, Epidemiology Forecast till 2030

DelveInsight Buisness Research LLP
DelveInsight’s ‘Angelman Syndrome Market Insights, Epidemiology, and Market Forecast – 2030’ report deliver an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of Angelman Syndrome in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Angelman Syndrome (AS) is a complex genetic disorder that primarily affects the nervous system. The characteristic features of this condition include delayed development, intellectual disability, severe speech impairment, and problems with movement and balance (ataxia).

 

Angelman Syndrome Epidemiology 

  • Total prevalent cases of Angelman Syndrome in 7 MM in 2017 was 57,716 
  • The prevalence of Angelman Syndrome in 2017
    • United States – 21,715 
    • Germany –  6,448
    • Spain – 3,917

 

Angelman Syndrome Epidemiology Segmentation in 7MM from 2017 to 2030

  • Total Prevalent cases of Angelman Syndrome
  • Diagnosed Prevalent Cases of Angelman Syndrome
  • Angelman Syndrome Cases by Mutation Types
  • Angelman Syndrome associated with Clinical Manifestations

 

Angelman Syndrome Market

The therapeutic Angelman Syndrome market in 7MM in 2017 was USD 255 Million 

 

Angelman Syndrome Market Drivers

  • Biomarker Studies
  • Increasing Prevalence of Angelman Syndrome
  • Molecular Level Diagnosis

 

Angelman Syndrome Market Barriers

  • Lack of awareness
  • Lack of late stage clinical trials
  • Lack of Data
  • Economic Burden

 

Angelman Syndrome Emerging Drugs

  1. Gaboxadol: Ovid Therapeutics
  2. GTX-101: GeneTx Biotherapeutics
  3. GT-AS/AGIL-AS: PTC Therapeutics

 

Request for sample pages

Table of contents

1 Key Insights

2 Executive Summary of Angelman Syndrome

3 SWOT Analysis for Angelman Syndrome

4 Angelman Syndrome Market Overview at a Glance

4.1 Market Share (%) Distribution of Angelman Syndrome in 2017

4.2 Market Share (%) Distribution of Angelman Syndrome in 2030

5 Disease Background and Overview

5.1 Introduction

5.2 Cause

5.3 Signs and Symptoms

5.4 Related Disorders and Differential Diagnosis

5.5 Complications

5.6 Genetics of Angelman syndrome

5.7 Molecular Genetic Pathogenesis

5.8 Diagnosis

5.8.1 Clinical criteria for diagnosis

5.8.2 Disease History and Medical Conditions

5.9 Diagnostic Algorithm

6 Epidemiology and Patient Population

6.1 Key Findings

6.2 7MM Total Prevalent Patient Population of Angelman syndrome

7 Country Wise-Epidemiology of Angelman syndrome

7.1 The United States

7.1.1 Assumptions and Rationale

7.1.2 Total Prevalent Cases of Angelman Syndrome in the United States

7.1.3 Diagnosed Prevalent Cases of Angelman Syndrome in the United States

7.1.4 Angelman Syndrome cases by Mutation Types in the United States

7.1.5 Angelman Syndrome associated with Clinical Manifestations in the United States

7.2 EU5

7.2.1 Assumptions and Rationale

7.3 Germany

7.3.1 Total Prevalent Cases of Angelman Syndrome in Germany

7.3.2 Diagnosed Prevalent Cases of Angelman Syndrome in Germany

7.3.3 Angelman Syndrome cases by Mutation Types in Germany

7.3.4 Angelman Syndrome associated with Clinical Manifestations in Germany

7.4 France

7.4.1 Total Prevalent Cases of Angelman Syndrome in France

7.4.2 Diagnosed Prevalent Cases of Angelman Syndrome in France

7.4.3 Angelman Syndrome cases by Mutation Types in France

7.4.4 Angelman Syndrome associated with Clinical Manifestations in France

7.5 Italy

7.5.1 Total Prevalent Cases of Angelman Syndrome in Italy

7.5.2 Diagnosed Prevalent Cases of Angelman Syndrome in Italy

7.5.3 Angelman Syndrome cases by Mutation Types in Italy

7.5.4 Angelman Syndrome associated with Clinical Manifestations in Italy

7.6 Spain

7.6.1 Total Prevalent Cases of Angelman Syndrome in Spain

7.6.2 Diagnosed Prevalent Cases of Angelman Syndrome in Spain

7.6.3 Angelman Syndrome cases by Mutation Types in Spain

7.6.4 Angelman Syndrome associated with Clinical Manifestations in Spain

7.7 The United Kingdom

7.7.1 Total Prevalent Cases of Angelman Syndrome in the United Kingdom

7.7.2 Diagnosed Prevalent Cases of Angelman Syndrome in the United Kingdom

7.7.3 Angelman Syndrome cases by Mutation Types in the UK

7.7.4 Angelman Syndrome associated with Clinical Manifestations in the UK

7.8 Japan

7.8.1 Assumptions and Rationale

7.8.2 Total Prevalent Cases of Angelman Syndrome in Japan

7.8.3 Diagnosed Prevalent Cases of Angelman Syndrome in Japan

7.8.4 Angelman Syndrome cases by Mutation Types in Japan

7.8.5 Angelman Syndrome associated with Clinical Manifestations in Japan

8 Treatment and Management of Angelman syndrome

8.1 Recommendations for the management of Angelman Syndrome

8.2 Future treatment options for Angelman Syndrome

8.2.1 Gene Therapy

8.2.2 Topoisomerase Inhibitors

8.2.3 Minocycline

8.2.4 Cannabidiol (CBD)

8.2.5 Protein Phosphatase 2A (PP2A) Inhibitor

9 Unmet Needs

10 Organizations contributing toward Angelman Syndrome

11 KOL’s Views: Angelman Syndrome

12 Patient Journey

12.1 Journey toward a Diagnosis: Diagnosing a Rare form of Angelman Syndrome

13 Case Reports

13.1 A Case of Fundus Oculi Albinoticus Diagnosed as Angelman Syndrome by Genetic Testing – A Japanese Case Study

13.2 Two Angelman families with unusually advanced neurodevelopment carry a start codon variant in the most highly expressed UBE3A isoform: a case report of US

13.3 Angelman Syndrome: A Case Series Assessing Neurological Issues in Adulthood – A European Case Report

14 Emerging Therapies

14.1 Gaboxadol: Ovid Therapeutics

14.1.1 Product Description

14.1.2 Other Development Activities

14.1.3 Clinical Development

14.1.4 Safety and Efficacy

14.2 GeneTx Biotherapeutics

14.2.1 GTX-102

15 Future Gene Therapies

15.1 GeneTx Biotherapeutics

15.1.1 GTX-101

15.2 PTC Therapeutics: GT-AS/AGIL-AS:

15.2.1 Product Description

15.2.2 Other Development Activities

15.3 Sarepta Therapeutics and StrideBio

15.3.1 Development Activities

16 Angelman syndrome: Seven Major Market Analysis

16.1 Key Findings

16.2 Market Size of Angelman Syndrome in 7MM

17 Market Outlook by Country

17.1 The United States: Market Outlook

17.1.1 United States Market Size

17.2 EU-5 Countries: Market Outlook

17.2.1 Germany

17.2.2 France

17.2.3 Italy

17.2.4 Spain

17.2.5 United Kingdom

17.3 Japan: Market Outlook

17.3.1 Total Market Size of Angelman syndrome

17.3.2 Market Size of Angelman Syndrome by Therapies

18 Market Drivers

19 Market Barriers

20 Market Access and Reimbursement

21 Appendix

21.1 Report Methodology

22 DelveInsight Capabilities

23 Disclaimer

24 About DelveInsight

Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Categories